- Home
- EPR vs PCVX Comparison
EPR vs PCVX Comparison
Compare EPR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPR
- PCVX
- Stock Information
- Founded
- EPR 1997
- PCVX 2013
- Country
- EPR United States
- PCVX United States
- Employees
- EPR N/A
- PCVX N/A
- Industry
- EPR Real Estate Investment Trusts
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- EPR Real Estate
- PCVX Health Care
- Exchange
- EPR Nasdaq
- PCVX Nasdaq
- Market Cap
- EPR 4.4B
- PCVX 4.0B
- IPO Year
- EPR 1997
- PCVX 2020
- Fundamental
- Price
- EPR $50.93
- PCVX $41.81
- Analyst Decision
- EPR Buy
- PCVX Strong Buy
- Analyst Count
- EPR 10
- PCVX 8
- Target Price
- EPR $58.19
- PCVX $114.17
- AVG Volume (30 Days)
- EPR 875.1K
- PCVX 1.5M
- Earning Date
- EPR 10-29-2025
- PCVX 11-04-2025
- Dividend Yield
- EPR 6.95%
- PCVX N/A
- EPS Growth
- EPR N/A
- PCVX N/A
- EPS
- EPR 2.29
- PCVX N/A
- Revenue
- EPR $707,150,000.00
- PCVX N/A
- Revenue This Year
- EPR $4.97
- PCVX N/A
- Revenue Next Year
- EPR $2.78
- PCVX N/A
- P/E Ratio
- EPR $22.30
- PCVX N/A
- Revenue Growth
- EPR 3.73
- PCVX N/A
- 52 Week Low
- EPR $41.75
- PCVX $27.66
- 52 Week High
- EPR $61.24
- PCVX $107.31
- Technical
- Relative Strength Index (RSI)
- EPR 40.68
- PCVX 51.58
- Support Level
- EPR $49.00
- PCVX $39.87
- Resistance Level
- EPR $50.34
- PCVX $45.90
- Average True Range (ATR)
- EPR 1.21
- PCVX 1.93
- MACD
- EPR -0.25
- PCVX -0.60
- Stochastic Oscillator
- EPR 37.61
- PCVX 32.20
About EPR EPR Properties
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.